Antipsychotics Library

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

Antipsychotics DMPK and Bioanalytical Services

Antipsychotic bioanalysis breaks the NADPH-only default. Five compounds — haloperidol, clozapine, risperidone, quetiapine, and aripiprazole — follow CYP Phase I metabolism with standard NADPH. Olanzapine requires CYP1A2 Phase I (NADPH) plus UGT1A4 Phase II glucuronidation (UDPGA). A NADPH-only protocol applied across all six captures Phase I for olanzapine but produces zero glucuronidation data — because the UGT cofactor was never added.

Creative Proteomics provides CYP Phase I metabolic profiling for NADPH-only substrates, dual-cofactor Phase I+II incubation for UGT1A4 substrates, CNS bioanalysis, and custom multi-antipsychotic panels.

Browse Drug Index Request Custom Method Support

Olanzapine Breaks the NADPH-Only DefaultUGT1A4 Phase II glucuronidation requires UDPGA. NADPH-only incubation misses it entirely.

Five NADPH-Only, One Dual-CofactorFive antipsychotics need NADPH. Olanzapine needs NADPH + UDPGA. One protocol cannot serve all six.

CNS-Specific Matrix ConsiderationsBrain and CSF bioanalysis with blood-brain barrier context — not just plasma quantification.

Antipsychotic Cofactor Risks DMPK Strategy Map

⚡

Cofactor Requirement ClassificationFive antipsychotics need NADPH-only. Olanzapine needs NADPH + UDPGA. Without UDPGA, UGT1A4 Phase II glucuronidation is never initiated.

🧬

CYP Phase I Metabolism (NADPH)Haloperidol (CYP3A4/2D6), clozapine (CYP1A2/3A4), risperidone (CYP2D6/3A4), quetiapine (CYP3A4), aripiprazole (CYP2D6/3A4) — standard NADPH supplementation.

📊

Phase I + II Dual-Cofactor (NADPH + UDPGA)Olanzapine: CYP1A2 Phase I (NADPH) + UGT1A4 Phase II glucuronidation (UDPGA). Both cofactors must be present in the same incubation.

🔬

CNS Matrix BioanalysisBrain homogenate and CSF quantification methods for antipsychotic compounds, combined with standard plasma PK profiling.

Antipsychotic cofactor audit before method development.Creative Proteomics determines whether the compound requires NADPH-only, or NADPH+UDPGA dual-cofactor incubation — because adding NADPH to an olanzapine incubation and omitting UDPGA produces CYP1A2 Phase I data but zero UGT1A4 glucuronidation data.

Antipsychotic Drug Index

Find the Antipsychotic Compound Behind the Study

Antipsychotic studies split by a key analytical question: does the compound follow CYP Phase I metabolism with standard NADPH cofactor, or CYP1A2 Phase I plus UGT1A4 Phase II requiring UDPGA? Use the index to classify the cofactor requirement and route the workflow accordingly. The drug panels are intentionally concise so detailed compound monographs can be added separately.

A–Z anchors

Filter by study tagsSelect a field to reveal its tags. Multiple tags work together as narrowing filters, so the drug index shows only antipsychotics matching all selected values.

6 entries · Page 1 of 3

Analytical Pain Points

What Drives Assay Failure in Antipsychotic Studies?

Antipsychotic DMPK assays fail when NADPH-only incubation is applied to olanzapine — a compound that also requires UDPGA for UGT1A4 Phase II glucuronidation. Phase II metabolism is silently omitted when the cofactor was never added.

Olanzapine Requires Dual-Cofactor Incubation

Olanzapine is metabolized by CYP1A2 (Phase I, NADPH) and UGT1A4 (Phase II, UDPGA). A NADPH-only incubation produces zero glucuronidation data because the required UGT cofactor was never added.

Our responseDual-cofactor (NADPH + UDPGA) incubations with Phase I and Phase II metabolite profiling.

Phase I & II Metabolite Characterization →

NADPH-Only Protocol Silently Omits UGT Metabolism

Standard CYP DMPK protocols use NADPH-only supplementation. Applied to olanzapine, UGT1A4 Phase II is never initiated. The Phase I data appears normal, and the Phase II omission is invisible.

Our responseCofactor audit at compound classification: NADPH-only for CYP substrates, NADPH+UDPGA for UGT substrates.

Custom LC-MS/MS Method Development →

Five NADPH-Only, One Dual-Cofactor

Five antipsychotics need NADPH. Olanzapine needs NADPH + UDPGA. Running all six through one panel without cofactor matching puts one group in the wrong incubation environment.

Our responsePanel-level cofactor matching: NADPH-only arms for CYP substrates, NADPH+UDPGA for olanzapine.

Custom Panels →

CNS Matrix: Brain, CSF, and Blood-Brain Barrier

Antipsychotic compounds target CNS tissue. Plasma-only bioanalysis quantifies systemic exposure but provides no data on brain penetration or CSF concentration.

Our responseCNS matrix bioanalysis with brain homogenate and CSF quantification combined with standard plasma PK profiling.

Complex Biological Matrices →

UGT1A4 Activity Varies Across Hepatocyte Donors

UGT1A4 expression is donor-dependent. Pooled microsomes average CYP activity but not necessarily UGT activity. A single-donor incubation may misrepresent glucuronidation capacity.

Our responseUGT1A4 activity-verified hepatocyte models with donor-level glucuronidation activity assessment.

Metabolite Identification →

Focused Service Paths

Four Practical Routes for Antipsychotic Studies

Antipsychotic workflows should be selected according to cofactor requirement: NADPH-only CYP Phase I metabolism for haloperidol, clozapine, risperidone, quetiapine, and aripiprazole; dual-cofactor NADPH+UDPGA Phase I+II metabolism for olanzapine; CNS matrix analysis for brain and CSF; or custom panels with cofactor-matched incubation arms.

CYP Phase I Metabolism & MetID (NADPH)

For haloperidol, clozapine, risperidone, quetiapine, and aripiprazole — standard NADPH-supplemented CYP Phase I metabolism in microsome/hepatocyte models.

Multi-CYP incubation (CYP3A4/2D6/1A2)
NADPH cofactor supplementation
Phase I metabolite profiling

Phase I & II Metabolite Characterization →

Phase I+II Dual-Cofactor Profiling (NADPH + UDPGA)

For olanzapine — dual-cofactor incubation with NADPH for CYP1A2 Phase I and UDPGA for UGT1A4 Phase II glucuronidation.

NADPH + UDPGA dual-cofactor incubation
CYP1A2 Phase I + UGT1A4 Phase II profiling
Glucuronide metabolite identification

Phase I & II Metabolite Characterization →

CNS Matrix Bioanalysis

For antipsychotic compounds requiring brain homogenate, CSF, and plasma quantification with blood-brain barrier permeability context.

Brain homogenate and CSF matrix methods
Plasma-to-brain concentration ratio determination
CNS-specific method adaptation

Complex Biological Matrices →

Custom Cofactor-Matched Antipsychotic Panel

For multi-antipsychotic studies with cofactor-matched incubation arms: NADPH-only for CYP substrates, NADPH+UDPGA for olanzapine, within one validated panel.

NADPH-only incubation arms for CYP substrates
NADPH+UDPGA incubation arms for olanzapine
Panel-level cofactor compatibility assessment

Custom Multi-Analyte Drug Panels →

Project Inquiry

Need Support for a Novel or Unlisted Antipsychotic?

If your antipsychotic compound involves CYP Phase I, UGT Phase II, or both — and requires cofactor-matched DMPK workflow design — Creative Proteomics defines the cofactor requirement and isoform profile before method development.

Creative Proteomics designs custom antipsychotic workflows by defining CYP isoform profile, UGT/Phase II status, cofactor requirement (NADPH only or NADPH+UDPGA), CNS matrix needs, biological system, and panel composition before building the analytical method.

Target antipsychotic

CYP isoform profile

UGT / Phase II status

Cofactor requirement

CNS matrix need

Panel requirements

Ready to Quantify Your Lead Compound or Metabolite?

Share your matrix type, sample count, and expected range—feasibility routing will confirm whether direct quantification is fit-for-purpose or method development is recommended.

Want to browse compounds, matrices, and assay coverage? Explore the Library →